Literature DB >> 7911694

Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line.

C Melguizo1, J Prados, J E Fernández, C Vélez, L Alvarez, A Aránega.   

Abstract

The emergence of drug-resistant tumor cells remains a major problem in cancer chemotherapy. Resistance to multiple unrelated antineoplastic drugs may be related, in part, to expression of the P-glycoprotein. The cell line RD, derived from an embryonic rhabdomyosarcoma tumor, was used as an in vitro model to examine the development of drug resistance. A cell line resistant to actinomycin D (RD-DAC) was developed by growing RD in increasing concentrations of the drug. The ID50 (concentration of drug needed to induce a 50% reduction in cell growth) of the resultant line to actinomycin D was more than 15 times that of the parental line. The resistant line was cross-resistant to vincristine and doxorubicin. Resistance to actinomycin D resulted in increased P-glycoprotein expression, which was associated with a change in desmin and vimentin expression. These results suggest that exposure to chemotherapeutic drugs can induce not only classical multidrug resistance, but also a process of cellular differentiation in rhabdomyosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911694

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  2 in total

1.  A dual-fluorescence high-throughput cell line system for probing multidrug resistance.

Authors:  Kyle R Brimacombe; Matthew D Hall; Douglas S Auld; James Inglese; Christopher P Austin; Michael M Gottesman; King-Leung Fung
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

2.  Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.

Authors:  Guido Seitz; Steven W Warmann; Christian O Vokuhl; Heike Heitmann; Claudia Treuner; Ivo Leuschner; Jörg Fuchs
Journal:  Pediatr Surg Int       Date:  2007-05       Impact factor: 2.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.